Gencove

Name: Gencove
Brand: Gencove

Sequencing solutions for global health and sustainability

Est 2016|Valuation $50M|Raised $16M|3 Ref Customers

LinkedIn 9K|Web traffic 1K|FTEs 15|HQ Long Island City, New York, US

01Competitive Landscape

Narrative analysis

- Feature differentiation: Gencove emphasizes imputation-centric, low-pass-first pipelines and delivery formats that can be used in place of arrays, including array-compatible deliverables. - Pricing and value: Illumina ICA provides more granular unit economics (published unit credits and per-compute license costs), which can aid forecasting. Gencove appears to be priced as a quote-based service/solution, which may be advantageous for bundled offers or disadvantageous for teams that require transparent list pricing. - When customers might choose competitors: - Choose Illumina ICA when an organization already operates within the Illumina ecosystem and prefers standardized pipelines with transparent unit rates. - Choose DNAnexus or Seven Bridges for broad workflow governance, collaboration features, and regulated research programs. - Choose open-source tooling when an organization has robust in-house bioinformatics and prefers maximum control and potential cost-optimization, accepting the integration and maintenance burden.

	Gencove	Illumina DRAGEN / ICA	DNAnexus
Starting Price	Not publicly listed (quote-based)	Usage-based model with published unit economics; DRAGEN license costs are reported per compute unit (pricing still depends on pipeline and compute)	Enterprise pricing varies; example marketplace listings show large annual subscription SKUs plus usage charges
Best For	Organizations prioritizing lpWGS and imputation workflows at scale, and those requiring species/breed reference panels and array-compatible deliverables	Illumina-centric labs needing high-performance secondary analysis and integration with Illumina systems	Enterprises needing a broad cloud genomics platform, workflow execution, collaboration, and governance
Key Strength	Focus on lpWGS imputation workflows and operational delivery (CLI/API), with cross-species support	Mature secondary analysis tooling and integration with Illumina sequencing products	Broad platform scope, enterprise procurement options, and governance features
Key Weakness	Limited public security and compliance documentation; narrower focus that may not suit teams needing broad multi-omics workflows	Less emphasis on lpWGS-specific reference panel strategies; cost models can be complex	Can be expensive and heavy-weight for teams that primarily require lpWGS imputation outputs

01Competitive Landscape

Narrative analysis

Feature differentiation: Gencove emphasizes imputation-centric, low-pass-first pipelines and delivery formats that can be used in place of arrays, including array-compatible deliverables.
Pricing and value: Illumina ICA provides more granular unit economics (published unit credits and per-compute license costs), which can aid forecasting. Gencove appears to be priced as a quote-based service/solution, which may be advantageous for bundled offers or disadvantageous for teams that require transparent list pricing.
When customers might choose competitors:
- Choose Illumina ICA when an organization already operates within the Illumina ecosystem and prefers standardized pipelines with transparent unit rates.
- Choose DNAnexus or Seven Bridges for broad workflow governance, collaboration features, and regulated research programs.
- Choose open-source tooling when an organization has robust in-house bioinformatics and prefers maximum control and potential cost-optimization, accepting the integration and maintenance burden.

	Gencove	Illumina DRAGEN / ICA	DNAnexus
Starting Price	Not publicly listed (quote-based)	Usage-based model with published unit economics; DRAGEN license costs are reported per compute unit (pricing still depends on pipeline and compute)	Enterprise pricing varies; example marketplace listings show large annual subscription SKUs plus usage charges
Best For	Organizations prioritizing lpWGS and imputation workflows at scale, and those requiring species/breed reference panels and array-compatible deliverables	Illumina-centric labs needing high-performance secondary analysis and integration with Illumina systems	Enterprises needing a broad cloud genomics platform, workflow execution, collaboration, and governance
Key Strength	Focus on lpWGS imputation workflows and operational delivery (CLI/API), with cross-species support	Mature secondary analysis tooling and integration with Illumina sequencing products	Broad platform scope, enterprise procurement options, and governance features
Key Weakness	Limited public security and compliance documentation; narrower focus that may not suit teams needing broad multi-omics workflows	Less emphasis on lpWGS-specific reference panel strategies; cost models can be complex	Can be expensive and heavy-weight for teams that primarily require lpWGS imputation outputs

Gencove

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map